Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma

Clin Cancer Res (2024)

https://doi.org/10.1158/1078-0432.CCR-24-0037

Published: 25 November 2024

View article titled, Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

Clin Cancer Res (2022) 28 (5): 915–927.

https://doi.org/10.1158/1078-0432.CCR-21-1816

Published: 01 March 2022

View article titled, Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

Ann Marie Egloff, Ju-Whei Lee, Corey J. Langer, Harry Quon, Alec Vaezi, Jennifer R. Grandis, Raja R. Seethala, Lin Wang, Dong M. Shin, Athanassios Argiris, Donghua Yang, Ranee Mehra, John Andrew Ridge, Urjeet A. Patel, Barbara A. Burtness, Arlene A. Forastiere

Clin Cancer Res (2014) 20 (19): 5041–5051.

https://doi.org/10.1158/1078-0432.CCR-14-0051

Published: 30 September 2014

View article titled, Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

Includes: Supplementary data

Journal Articles

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Neil D. Gross, Julie E. Bauman, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang, Simion Chiosea, Brian L. Hood, Melanie S. Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Seungwon Kim, Athanassios Argiris, Lori Wirth, Marina N. Nikiforova, Jill M. Siegfried, Jennifer R. Grandis

Clin Cancer Res (2014) 20 (12): 3289–3298.

https://doi.org/10.1158/1078-0432.CCR-13-3360

Published: 12 June 2014

View article titled, Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Includes: Supplementary data

Journal Articles

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Patrick J. Schuler, Malgorzata Harasymczuk, Carmen Visus, Albert DeLeo, Sumita Trivedi, Yu Lei, Athanassios Argiris, William Gooding, Lisa H. Butterfield, Theresa L. Whiteside, Robert L. Ferris

Clin Cancer Res (2014) 20 (9): 2433–2444.

https://doi.org/10.1158/1078-0432.CCR-13-2617

Published: 30 April 2014

View article titled, Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Includes: Supplementary data

Journal Articles

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

Sarah Wheeler, Doris R. Siwak, Raymond Chai, Courtney LaValle, Raja R. Seethala, Lin Wang, Kathleen Cieply, Carol Sherer, Corwin Joy, Gordon B. Mills, Athanassios Argiris, Jill M. Siegfried, Jennifer R. Grandis, Ann Marie Egloff

Clin Cancer Res (2012) 18 (8): 2278–2289.

https://doi.org/10.1158/1078-0432.CCR-11-1593

Published: 16 April 2012

View article titled, Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Athanassios Argiris, Austin G. Duffy, Shivaani Kummar, Nicole L. Simone, Yoshio Arai, Seungwon W. Kim, Susan F. Rudy, Vishnu R. Kannabiran, Xinping Yang, Minyoung Jang, Zhong Chen, Nanette Suksta, Theresa Cooley-Zgela, Susmita G. Ramanand, Aarif Ahsan, Mukesh K. Nyati, John J. Wright, Carter Van Waes

Clin Cancer Res (2011) 17 (17): 5755–5764.

https://doi.org/10.1158/1078-0432.CCR-11-0861

Published: 01 September 2011

View article titled, Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Includes: Supplementary data

Journal Articles

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

Alec Vaezi, XiaoZhe Wang, Shama Buch, William Gooding, Lin Wang, Raja R. Seethala, David T. Weaver, Alan D. D'Andrea, Athanassios Argiris, Marjorie Romkes, Laura J. Niedernhofer, Jennifer R. Grandis

Clin Cancer Res (2011) 17 (16): 5513–5522.

https://doi.org/10.1158/1078-0432.CCR-11-0086

Published: 14 August 2011

View article titled, XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

Includes: Supplementary data

Journal Articles

Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab

Neil E. Bhola, Sufi M. Thomas, Maria Freilino, Sonali Joyce, Anirban Sahu, Jessica Maxwell, Athanassios Argiris, Raja Seethala, Jennifer R. Grandis

Clin Cancer Res (2011) 17 (15): 4996–5004.

https://doi.org/10.1158/1078-0432.CCR-10-3406

Published: 31 July 2011

View article titled, Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab

Includes: Supplementary data

Journal Articles

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Ahmad Tarhini, Athanasios Kotsakis, William Gooding, Yongli Shuai, Daniel Petro, David Friedland, Chandra P. Belani, Sanja Dacic, Athanassios Argiris

Clin Cancer Res (2010) 16 (23): 5900–5907.

https://doi.org/10.1158/1078-0432.CCR-10-0802

Published: 06 December 2010

View article titled, Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Journal Articles

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

Mary J. Fidler, Athanassios Argiris, Jyoti D. Patel, David H. Johnson, Alan Sandler, Victoria M. Villaflor, John Coon, IV, Lela Buckingham, Kelly Kaiser, Sanjib Basu, Philip Bonomi

Clin Cancer Res (2008) 14 (7): 2088–2094.

https://doi.org/10.1158/1078-0432.CCR-07-4013

Published: 01 April 2008

View article titled, The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

Journal Articles

Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck

Michael T. Milano, Daniel J. Haraf, Kerstin M. Stenson, Mary Ellyn Witt, Cathy Eng, Bharat B. Mittal, Athanassios Argiris, Harold Pelzer, Mark F. Kozloff, Everett E. Vokes

Clin Cancer Res (2004) 10 (15): 4922–4932.

https://doi.org/10.1158/1078-0432.CCR-03-0634

Published: 05 August 2004

View article titled, Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck

Journal Articles

Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

Athanassios Argiris, Bruce E. Brockstein, Daniel J. Haraf, Kerstin M. Stenson, Bharat B. Mittal, Merrill S. Kies, Fred R. Rosen, Borko Jovanovic, Everett E. Vokes

Clin Cancer Res (2004) 10 (6): 1956–1962.

https://doi.org/10.1158/1078-0432.CCR-03-1077

Published: 24 March 2004

View article titled, Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

Journal Articles

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Athanassios Argiris, Chun-Xia Wang, Steve G. Whalen, Michael P. DiGiovanna

Clin Cancer Res (2004) 10 (4): 1409–1420.

https://doi.org/10.1158/1078-0432.CCR-1060-02

Published: 20 February 2004

View article titled, Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Journal Articles

Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer

Daniel J. Haraf, Fred R. Rosen, Kerstin Stenson, Athanassios Argiris, Bharat B. Mittal, Mary Ellyn Witt, Bruce E. Brockstein, Marcy A. List, Louis Portugal, Harold Pelzer, Ralph R. Weichselbaum, Everett E. Vokes

Clin Cancer Res (2003) 9 (16): 5936–5943.

Published: 15 December 2003

View article titled, Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer

NARROW

Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck

Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only